Analysts have suggested that Tezspire could become a $1 billion-plus ... such as Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's IL-5 inhibitor Fasenra (benralizumab ...

Dupixent becomes the first-ever targeted therapy ... after Amgen and AstraZeneca’s TSLP-targeting severe asthma therapy Tezspire (tezepelumab) showed signs of efficacy in COPD in a mid-stage ...